Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics cash
Cash and short-term investments held at the end of each period.
Nurix Therapeutics's cash was $1.10B at Aug 31, 2026. For fiscal 2025 it was $592.90M, down 2.7% from the year before. The highest annual figure on record is $609.60M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $592.90M | -2.7% |
| FY2024 | Nov 30, 2024 | $609.60M | +111.7% |
| FY2023 | Nov 30, 2023 | $287.90M | -6.9% |
| FY2022 | Nov 30, 2022 | $309.10M | +4.5% |
| FY2021 | Nov 30, 2021 | $295.70M | +5.2% |
| FY2020 | Nov 30, 2020 | $281.15M | +645.4% |
| FY2019 | Nov 30, 2019 | $37.72M | +47.4% |
| FY2018 | Nov 30, 2018 | $25.59M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $1.10B | +156.5% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $443.50M | -8.7% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $540.70M | -1.6% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | $592.90M | -2.7% |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $428.80M | -4.3% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $485.80M | +9.6% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $549.70M | +125.3% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | $609.60M | +111.7% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $448.10M | +73.1% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $443.10M | +57.6% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $244.00M | -11.9% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $287.90M | -6.9% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $258.90M | -24.8% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $281.20M | -5.4% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $277.10M | +5.8% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $309.10M | +4.5% |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $344.48M | +0.2% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $297.28M | -23.0% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $261.98M | -13.6% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | $295.70M | +5.2% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $343.90M | -2.9% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $386.02M | +142.3% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $303.07M | +437.3% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $281.15M | +645.4% |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $354.24M | +583.2% |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $159.33M | +522.6% |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $56.41M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $37.72M | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | $51.85M | – |
| Q4 FY2018CQ4 2018 | Nov 30, 2018 | $25.59M | – |
See a number that looks wrong?